OTC:NMDBF
CSE:NEON

NeonMind Biosciences


NeonMind Biosciences Inc manufactures Medicinal Mushroom products under the brand NeonMind which are for sale through e-commerce on its website. It is also in the early stages of development of a product with the goal of using such product to promote and cause weight loss using a compound found in psychedelic mushrooms. The company’s product development is organized into two divisions long-term product development, and near term product commercialization.

NeonMind Biosciences News

  • NeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC to Its Specialty Clinics Advisory Board
  • NeonMind to Present at H.C. Wainwright Bioconnect Conference
  • NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference
  • NeonMind Announces Successful Completion of Pre-IND Consultation with FDA on Clinical Path for Obesity Drug Candidate NEO-001
  • NeonMind to Participate in Panel Discussion at Lift & Co. Expo's Psychedelics Business Summit on November 19, 2021
  • NeonMind and SRx Health Solutions Announce Strategic Alliance to Establish Specialty Mental Health Clinics for Interventional Psychiatry Treatments
  • NeonMind Biosciences Named as a Top Industry Innovator in Inaugural Issue of Psychedelia Magazine
  • KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
© 2020 - 2022 Biotech Stock Market Report